

NovaBay Pharmaceuticals, Inc.

Q4 about inline, but 2022 revenue guidance strong. Major acquisition of DERMAdoctor highly positive and should drive strong growth. Raising P/T to \$4.25.

Q4 about inline: NovaBay recently (on March 29) reported its Q4 (ending December) 2021 results. Revenue was \$2.6 million (+40% y-o-y), compared with our and consensus estimates of \$3.3 – 3.4 million. Net loss was \$0.9 million or EPS of \$(0.02) compared with our and consensus estimates of \$(0.03) – (0.05). There was no company guidance.

Avenova growth again: Avenova sales were \$1.6 million, up ~7% y-o-y. Unit sales along with OTC (over the counter) and DTC (direct to consumer) sales were +13% y-o-y.

DERMAdoctor contribution: DERMAdoctor product sales were \$0.6 million, which reflects only about 1/2 a quarter of sales since the acquisition closed near mid-November.

Major acquisition of DERMAdoctor: In September, NovaBay announced the acquisition of privately held DERMAdoctor for ~\$12 million (in cash). The deal closed in November.

DERMAdoctor: DERMAdoctor produces and sells more than 30 products under lines that include Ain't Misbehavin', Calm Cool + Corrected, Kakadu C, KP Duty, and Wrinkle Revenge. Its products are designed to address acne, aging skin, dark spots, dry skin, eczema, and many other skin conditions. DERMAdoctor sells its products through major retailers such as Macy's, QVC, Costco, digital beauty retailers such as SkinStore and Amazon, as well as its own website. DERMAdoctor also has a large and growing network of international distributors and retailers. DERMAdoctor's management has joined the NovaBay management team.

Strong 2022 guidance: The company maintained 2022 revenue guidance of \$20 million, mainly driven from its DERMAdoctor acquisition.

Adjusting 2022 estimates slightly: We are maintaining our 2022 revenue estimate of \$20 million, but adjusting EPS to (0.07) from (0.06). We are initiating our 2023 estimates for revenue of \$25 million, and for EPS of (0.02).

Management long term positive: NovaBay is making good progress to market its Avenova product to the 41 million Americans (\$600 million market opportunity) who suffer from blepharitis and related eye symptoms. In addition, the acquisition of DERMAdoctor allows strong growth and synergy opportunities in the global market for cosmetic skincare products. NovaBay plans to launch a broad range of complementary eye and skin care products. The company also plans to leverage operational synergies and sales/distribution relationships.

We remain positive: Despite stock and financial results volatility, we believe that NovaBay is a compelling investment story. The company's focus in 2022 is to drive Avenova and DERMAdoctor sales to consumers. The company will also continue to target ophthalmic and skin care consumer product line extensions for acquisition or licensing opportunities.

Balance sheet steady: In Q4, the company raised \$15 million for its DERMAdoctor acquisition (selling ~37.5 million shares at \$0.53/share). We believe the company has enough cash into 2023.

Risk/reward positive: Maintaining our BUY rating, but raising our 12-month price target to \$4.25 from \$4.00, which is based on an NPV analysis. Although there are many variables in our valuation (many with high variabilities and risks), we believe this appropriately balances out the company's high risks with its high growth prospects and large upside opportunities.

Company Description

Based in Emeryville, CA, NovaBay Pharmaceuticals is a biopharmaceutical company focusing on commercializing and developing therapeutics for the anti-infective market.

United States Healthcare

April 11, 2022

Edward Woo, CFA (949) 259-4932 ewoo@ascendiant.com

Stock Data

Exchange:	NYSE
52-week Range:	\$0.26 - 0.88
Shares Outstanding (million):	96
Market cap (\$million):	\$27
EV (\$million):	\$19
Debt (\$million):	\$0
Cash (\$million):	\$8
Avg. Daily Trading Vol. (\$million):	\$0.4
Float (million shares):	36
Short Interest (million shares):	1
Dividend, annual (yield):	\$0 (NA%)

Revenues (US\$ million)

	<u>2022E</u> <u>(Cur.)</u>	<u>2022E</u> (Old)	<u>2023E</u> (Cur.)	<u>2023E</u> (Old)
Q1 Mar	3E	4E	5E	
Q2 Jun	4E		5E	
Q3 Sep	6E		7E	
Q4 Dec	<u>7E</u>	<u>6E</u>	<u>8E</u>	
Total	20E		25E	
EV/Revs	1.0x		0.8x	

Earnings per Share (pro forma)

	<u>2022E</u> (Cur.)	<u>2022E</u> (Old)	<u>2023E</u> (Cur.)	<u>2023E</u> (Old)
Q1 Mar	(0.04)E	(0.02)E	(0.02)E	
Q2 Jun	(0.03)E	(0.02)E	(0.02)E	
Q3 Sep	(0.01)E		0.00E	
Q4 Dec	<u>0.00E</u>	<u>(0.01)E</u>	<u>0.01E</u>	
Total	(0.07)E	(0.06)E	(0.02)E	
P/E	N/A		N/A	

Important Disclosures

Ascendiant Capital Markets LLC seeks to do business with companies covered by its research team. Consequently, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making an investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report, beginning on page 11.

Rating: BUY

COMPANY

UPDATE

Ticker:	NBY
Price:	\$0.28
Target: (fro	\$4.25 om \$4.00)



Exhibit 1: Company Strategy

NovaBay Overview

- Established Avenova[®] as the No. 1 antimicrobial lid and lash spray in the U.S. dry eye market
- Multi-pronged commercial distribution strategy
 - · Available direct-to-consumer without a prescription
 - Online channels like Amazon.com, Walmart.com, CVS.com, and Avenova.com
 - CVS Pharmacy stores across the U.S.
 - · Rx only available through pharmacies and physician offices
- Commercializing CelleRx[®] Clinical Reset[™] into the beauty market using the same pure, patented, FDA-cleared hypochlorous acid (HOCI)
 - · 40mL available direct-to-consumer without a prescription
 - Available on CelleRx.com

Investment Highlights

- Avenova is established in the \$4 billion U.S. dry eye market with differentiated positioning and multiple product-specific features and benefits
- Avenova is the only commercial hypochlorous acid (HOCI) spray clinically proven to treat the underlying cause rather than the symptoms of bacterial dry eye
- Growing DTC channel for prescription-strength Avenova provides stable pricing and product accessibility
- Record Avenova OTC unit sales in 4 most recent consecutive quarters
- Consumer launch in 4Q'20 of CelleRx Clinical Reset, allowing NovaBay to enter the large beauty market
- New initiatives are underway to increase sales and expand customer base through refreshed digital marketing programs and brick-and-mortar presence
- Strong cash position of \$10.3 million as of June 30, 2021 supports expanded business initiatives
- Strategy to acquire or license complementary products to leverage competencies in the ophthalmic and skincare markets and drive profitable growth



Exhibit 2: Avenova

Avenova Advantages

- Clinical study confirms Avenova's ability to reduce bacteria on ocular surface by >90%, not merely treat the symptoms
- Kills >20 microorganisms connected to common eye infections within seconds; effective against a range of pathogens including Staphylococcus
- Stable formulation distributed in glass bottle to protect against HOCI breakdown

LARENT SOLUTION The LARENT SOLUTION The LARENT SOLUTION PURE HYPOCHLOROUS AGID, 0.0196 AGID, 0.

Avenova Market Opportunity






Exhibit 3: Strategic Plan

Strategy for Growth

- Driving Avenova and CelleRx Clinical Reset sales to consumers
 - DTC channel presents the greatest opportunity for growth
 - Enhanced e-commerce, digital marketing and advertising programs, and refreshed branding
 - · Expanded online access and new brick-and-mortar availability
- Executing on strategy to target ophthalmic and skin care consumer product line extensions for acquisition or licensing opportunities
 - · Leverage established commercial operations
 - Capitalize on relationships with industry professionals

Source: Company report

Exhibit 4: Acquisition of DERMAdoctor (announced September 2021 & closed November 2021)

NovaBay/DERMAdoctor Synergies & Transaction Terms

- Financial Benefits
 - · Acquisition is expected to be immediately accretive to NovaBay's bottom line
 - Acquisition has the potential to double topline revenue in 2022
 - Higher revenue and operational synergies expected to drive profitability
- DERMAdoctor products complement NovaBay's CelleRx Clinical Reset[™]
 Scientifically formulated to be highly effective yet gentle on skin
- Leverage NovaBay's expertise in digital direct-to-consumer sales
- Creates an equal presence in the eyecare and skincare markets
 - New products will diversify NovaBay's revenue
- Transaction
 - \$12 million in cash; \$3 million in earnouts based on meeting financial targets
 - Expected to close in Q4 2021, subject to closing conditions

DERMAdoctor is an ideal fit to enhance shareholder value in very large and growing skincare market



Exhibit 5: DERMAdoctor Overview

DERMAdoctor Overview

- Privately held company selling skincare products developed by a board-certified dermatologist
- Brand portfolio encompasses several families of products
- Products focused on addressing dry skin, blemishes, keratosis pilaris and aging and are elegant, hypoallergenic, multitasking, problem-solving and highly effective.
- Products are marketed and distributed through various channels:
 - Online channels including Amazon.com, SkinStore.com and Dermadoctor.com
 - · Major retailers such as Macy's, QVC and Costco
 - International distribution in Asia and the Middle East



DERMAdoctor Primary Products






Exhibit 6: NovaBay and DERMAdoctor Market Opportunities

Expansion Opportunities in the Skincare Market

- Increase NovaBay's presence in the skincare market with the addition of more than 30 DERMAdoctor products
- Products are highly complementary to CelleRx brand
- Combination of companies provide exceptional opportunities for future sales growth
- Dr. Audrey Kunin appointed as NovaBay's Chief Product Officer
 - As an industry trailblazer, Dr. Kunin will lead R&D efforts to create new products and establish new brands in both the skincare and eyecare markets



Growing Into An Expanding Market

- Estimated global market for cosmetic skincare products to exceed \$145 billion in 2020 and reach \$185 billion by 2027
- Skincare, as a market segment, is growing faster than any other part of the beauty industry.
- This is our growth opportunity!
 - DERMAdoctor commercialize existing pipeline of new products
 - CelleRx develop complementary products
 - Luxury Brand X launch new innovative high-end line of skincare products designed to target the same market as Dr. Barbara Sturm, Augustinus Bader and Goop

2022 Corporate Vision for Combined Companies


A combined company equally diversified across the eyecare and skincare markets

Total revenue in excess of \$20M 50% eyecare / 50% skincare

Positive EBITDA







Source: https://bigcharts.marketwatch.com/

Exhibit 8: Consensus Expectations (as of March 29, 2022)

	Revenue (mils) 2021E	<u>2022E</u>		EPS <u>2021E</u>	<u>2022E</u>
Q1 Mar	\$2A	\$4E	Q1 Mar	\$(0.04)A	\$(0.03)E
Q2 Jun	\$2A		Q2 Jun	\$(0.04)A	
Q3 Sep	\$2A		Q3 Sep	\$(0.05)A	
Q4 Dec	\$3E		Q4 Dec	\$(0.05)E	
Total	\$9E	\$20E	Total	\$(0.18)E	\$(0.07)E

*Quarterly estimates may not add to annual estimates due to variations in contributing estimates and rounding

Source: Company report, Refinitiv, and Ascendiant Capital Markets estimates



FINANCIAL MODEL

NovaBay Pharmaceuticals, Inc.

Income Statement (\$ mils)	Mar-20		Cam 20	Dec-20	2020	Mar-21	Jun-21	Cam 04	Dec-21	2021	Mar-22	Lun 22	Com 22	Dec-22	2022	Mar-23	Jun-23	Cam 00	Dec-23	2023
Fiscal Year End: December 31	Q1A	Jun-20 Q2A	Sep-20 Q3A	Q4A	2020 FY-A	Q1A	Q2A	Sep-21 Q3A	Q4A	FY-A	Q1E	Jun-22 Q2E	Sep-22 Q3E		FY-E	Q1E	Q2E	Sep-23 Q3E	Q4E	2023 FY-E
FISCAL Year End: December 31	Q1A	QZA	Q3A	Q4A	FY-A	Q1A	QZA	Q3A	Q4A	FY-A	QTE	Q2E	Q3E	Q4E	FT-E	QIE	Q2E	Q3E	Q4E	FT-E
Sales Revenue	1.9	4.0	2.2	1.9	9.9	1.8	2.1	1.8	2.6	8.4	3.0	4.0	6.0	7.0	20.0	5.0	5.0	7.0	8.0	25.0
License/collaboration/distrib.	1.9	4.0	2.2	1.9	0.0	1.0	2.1	1.0	2.0	0.4	3.0	4.0	0.0	7.0	20.0	5.0	5.0	7.0	0.0	25.0
Other		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0					0.0					0.0
Total Revenue	1.9	<u>0.0</u> 4.0	<u>0.0</u> 2.2	<u>0.0</u> 1.9	<u>0.0</u> 9.9	<u>0.0</u> 1.8	<u>0.0</u> 2.1	<u>0.0</u> 1.8	<u>0.0</u> 2.6	<u>0.0</u> 8.4	3.0	4.0	6.0	7.0	20.0	5.0	5.0	7.0	8.0	25.0
Total Revenue	1.9	4.0	2.2	1.9	9.9	1.0	2.1	1.0	2.0	0.4	3.0	4.0	0.0	7.0	20.0	5.0	5.0	7.0	0.0	25.0
Cost of Revenues	0.6	2.0	0.5	0.8	4.0	0.5	0.6	0.5	1.2	2.8	1.2	1.4	1.8	1.8	6.2	1.3	1.3	1.8	2.0	6.3
Gross Profit	1.3	1.9	1.6	1.1	6.0	1.3	1.5	1.3	1.4	5.6	1.8	2.6	4.2	5.3	13.9	3.8	3.8	5.3	6.0	18.8
	-										-									
Research and development	0.0	0.1	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.2	0.8	0.2	0.2	0.2	0.2	0.8
Selling and marketing	1.6	1.4	1.7	1.5	6.2	1.7	1.8	1.9	1.9	7.2	3.0	3.0	3.0	3.0	12.0	3.0	3.0	3.0	3.0	12.0
General and administrative	1.3	1.5	1.9	1.3	5.9	1.2	1.6	1.8	2.7	7.2	2.0	2.0	2.0	2.0	8.0	2.0	2.0	2.0	2.0	8.0
Restructuring, litigation, and c					<u>0.0</u>					0.0	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>	<u>0.0</u>
Total operating expenses	2.8	3.0	3.7	2.8	12.4	2.9	3.4	3.6	4.6	14.5	5.2	5.2	5.2	5.2	20.8	5.2	5.2	5.2	5.2	20.8
O	(4.5)		(0.4)	(4.0)	(0.1)	(4.5)	(4.0)	(0.0)	(0.0)	(0.0)	(0.4)	(0.0)	(4.0)		(7.0)	4.5	(4.5)	~ ~		(0.4)
Operating income (loss)	(1.5)	(1.1)	(2.1)	(1.8)	(6.4)	(1.5)	(1.9)	(2.3)	(3.2)	(8.9)	(3.4)	(2.6)	(1.0)	0.0	(7.0)	(1.5)	(1.5)	0.0	0.8	(2.1)
										0.5										0.0
Interest income (expense)	(0.0)	(0.4)	(4.0)	0.0	0.0					0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other income (expense)	<u>(0.0)</u>	<u>(3.4)</u>	(<u>1.2</u>)	0.0	<u>(4.6)</u>	0.0	(4.0)	(0.0)	2.3	2.3	<u>0.0</u>	0.0	<u>0.0</u>	<u>0.0</u>	0.0	<u>0.0</u>	0.0	<u>0.0</u>	<u>0.0</u>	0.0
Income before income taxes	(1.6)	(4.5)	(3.2)	(1.8)	(11.0)	(1.5)	(1.9)	(2.3)	(0.9)	(6.6)	(3.4)	(2.6)	(1.0)	0.0	(7.0)	(1.5)	(1.5)	0.0	0.8	(2.1)
Income taxes	0.0	0.0	(2.2)	0.0	0.0	(4.5)	(4.0)	(2.2)	(0.0)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income (loss)	(1.6)	(4.5)	(3.2)	(1.8)	(11.0)	(1.5)	(1.9)	(2.3)	(0.9)	(6.6)	(3.4)	(2.6)	(1.0)	0.0	(7.0)	(1.5)	(1.5)	0.0	0.8	(2.1)
Nonrecurring/noncash adjustme	nts				0.0					0.0					0.0					0.0
Net income (pro forma)	(1.6)	(4.5)	(3.2)	(1.8)	(11.0)	(1.5)	(1.9)	(2.3)	(0.9)	(6.6)	(3.4)	(2.6)	(1.0)	0.0	(7.0)	(1.5)	(1.5)	0.0	0.8	(2.1)
		,	. ,				,	,		(/							,			• • •
EBITDA	(1.5)	(0.9)	(1.7)	(1.6)	(5.6)	(1.3)	(1.5)	(2.0)	(2.7)	(7.6)	(3.1)	(2.3)	(0.7)	0.4	(5.6)	(1.1)	(1.1)	0.4	1.2	(0.7)
Shares, Basic	28.0	30.4	40.0	41.8	35.1	41.8	42.6	44.9	45.3	43.7	96.0	96.1	96.2	96.3	96.2	96.4	96.5	96.6	96.7	96.6
Shares, Diluted	28.0	30.4	40.0	41.8	35.1	41.8	42.6	44.9	45.3	43.7	96.0	96.1	96.2	96.3	96.2	96.4	96.5	96.6	96.7	96.6
EPS Basic (Pro forma)	(\$0.06)	(\$0.15)	(\$0.08)	11 C C C	(\$0.31)	(\$0.04)		(\$0.05)	- C	(\$0.15)	(\$0.04)	(\$0.03)	(\$0.01)	\$0.00	(\$0.07)		(\$0.02)	\$0.00	\$0.01	(\$0.02)
EPS Diluted (Pro forma)	(\$0.06)	(\$0.15)	(\$0.08)	(\$0.04)	(\$0.31)	(\$0.04)	(\$0.04)	(\$0.05)	(\$0.02)	(\$0.15)	(\$0.04)	(\$0.03)	(\$0.01)	\$0.00	(\$0.07)	(\$0.02)	(\$0.02)	\$0.00	\$0.01	(\$0.02)
Margins																				
Gross margin (for product re-	69%	49%	75%	57%	60%	75%	71%	73%	54%	67%	60%	65%	70%	75%	69%	75%	75%	75%	75%	75%
Research and development	0%	3%	6%	2%	3%	0%	1%	1%	0%	1%	7%	5%	3%	3%	4%	4%	4%	3%	3%	3%
Sales and marketing	82%	36%	78%	79%	62%	93%	84%	101%	72%	86%	100%	75%	50%	43%	60%	60%	60%	43%	38%	48%
General and administrative	67%	37%	87%		60%	66%	74%	96%	103%	86%	67%	50%	33%	29%	40%	40%	40%	29%	25%	32%
Operating margin	-81%	-27%	-95%	-93%	-65%	-85%	-87%	-124%	-121%	-105% 0%	-113%	-65%	-17%	1%	-35%	-29%	-29%	1%	10%	-8%
Tax rate, GAAP	0%	0%	0%	0% -93%	0%	0%	0%	0%	0%	• / •	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Net margin	-84%	-113%	-148%	-93%	-111%	-85%	-87%	-124%	-34%	-78%	-113%	-65%	-17%	1%	-35%	-29%	-29%	1%	10%	-8%
Y/Y % change																				
Total Revenue	27%	123%	34%	11%	51%	-5%	-46%	-15%	40%	-15%	67%	88%	226%	165%	138%	67%	25%	17%	14%	25%
Gross margin	14%	40%	35%	-3%	23%	3%	-22%	-18%	33%	-5%	34%	71%	212%	268%	146%	108%	44%	25%	14%	35%
Research and development	-89%	259%	155%		55%	-44%	-82%	-92%	-75%	-84%	3900%	852%	1900%	2122%	1678%	0%	0%	0%	0%	0%
Sales and marketing	-56%	-7%	10%	-31%	-30%	8%	26%	10%	27%	17%	79%	68%	62%	58%	66%	0%	0%	0%	0%	0%
General and administrative	-20%	23%	41%	11%	12%	-7%	6%	-6%	109%	22%	68%	27%	13%	-26%	10%	0%	0%	0%	0%	0%
Operating income (loss)	-62%	-22%	20%		-32%	-1%	74%	11%	82%	38%	123%	40%	-56%	-102%	-22%	-57%	-44%	-105%	1500%	-71%
Net income (loss)	-62%	79%	1042%	-50%	6%	-4%	-59%	-29%	-49%	-41%	123%	40%	-56%	-106%	6%	-57%	-44%	-105%	1500%	-71%
EPS Diluted (Pro forma)	-77%	6%	389%	-67%	-36%	-36%	-70%	-37%	-53%	-52%	-3%	-38%	-80%	-103%	-52%	-58%	-44%	-105%	1493%	-71%
Source: Company reports and As		· Canital	Martiata	a a time a ta	-	I					1					1				

Source: Company reports and Ascendiant Capital Markets estimates.



NovaBay Pharmaceuticals, Inc.

Balance Sheet (\$ mils)	Mar-20	Jun-20	Sep-20				-				Sep-22			Jun-23	Sep-23	Dec-23
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1E	Q2E	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
_																
Assets																
Cash and cash equivalents	5.7	8.8	13.4	12.0	10.5	10.3	9.0	7.5	4.1	1.5	0.5	0.6	(0.9)	(2.3)	(2.3)	(1.5
Short term investments																
Accounts receivable, net	1.0	1.4	1.1	1.1	1.0	1.2	0.8	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7	1.7
Inventory	0.6	0.6	0.8	0.6	0.9	0.7	1.0	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2
Prepaid expenses and other	0.7	<u>1.1</u>	0.7	0.6	<u>0.8</u>	0.6	0.7	<u>0.8</u>	<u>0.8</u>	<u>0.8</u>						
Total current assets	7.9	11.9	16.0	14.2	13.1	12.8	11.5	13.2	9.8	7.2	6.2	6.2	4.8	3.3	3.4	4.2
Property and equipment, net	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2
Intangibles								9.7	9.7	9.7	9.7	9.7	9.7	9.7	9.7	9.7
Other_	<u>1.5</u>	1.3	1.0	0.9	0.8	0.7	0.6	0.9	0.9	<u>0.9</u>	<u>0.9</u>	<u>0.9</u>	<u>0.9</u>	<u>0.9</u>	<u>0.9</u>	<u>0.9</u>
Total assets	9.5	13.3	17.1	15.2	14.1	13.6	12.2	24.0	20.6	18.0	17.0	17.0	15.6	14.1	14.2	15.0
Liabilities and stockholders' equity	,															
Accounts payable	0.6	1.3	0.8	0.3	0.8	0.2	1.4	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Accrued expenses	2.1	1.9	2.1	2.5	1.9	2.2	1.5	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3	2.3
Deferred revenue	0.6	0.5			0.4				0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Short term debt	2.2	0.5	0.1					0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Total current liabilities	5.5	4.3	3.0	2.8	3.1	2.4	2.9	3.4	3.4	3.4	3.4	3.4	3.4	3.4	3.4	3.4
Deferred revenue									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other long term liabilities	0.4	0.3	0.2	0.1	0.0	0.0	0.0	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8	0.8
Warrant liabilities	3.9	7.7						9.6	9.6	9.6	9.6	9.6	9.6	9.6	9.6	9.6
Long term debt									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total other liabilities	4.3	8.0	0.2	0.1	0.0	0.0	0.0	10.4	10.4	10.4	10.4	10.4	10.4	10.4	10.4	10.4
Preferred stock								0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7	0.7
Common stock	0.3	0.3	0.4	0.4	0.4	0.4	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
Additional paid-in capital	126.0	131.7	147.8	148.0	148.1	150.2	150.6	150.9	150.9	150.9	150.9	150.9	150.9	150.9	150.9	150.9
Retained earnings					-						(148.9)				(151.7)	
Accumulated other comprehensive			(/	(<i>)</i>	· · · · ·	(,	· · ·	· · · ·	,	,	(/	< /	(,	(- <i>)</i>	(-)	
<u>Other</u>									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total stockholders' equity	(0.3)	1.0	13.9	12.3	11.0	11.2	9.4	10.2	6.8	4.2	3.2	3.2	1.8	0.3	0.4	1.2
Total stockholders' equity and liab	oili 9.5	13.3	17.1	15.2	14.1	13.6	12.2	24.0	20.6	18.0	17.0	17.0	15.6	14.1	14.2	15.0
Total stockholders equity and hat	JII 9.5	13.3	17.1	15.2	14.1	13.0	12.2	24.0	20.0	10.0	17.0	17.0	15.0	14.1	14.2	15.0

Balance Sheet Drivers

Balance encor Billione																
	Mar-20	Jun-20	Sep-20	Dec-20	Mar-21	Jun-21	Sep-21	Dec-21	Mar-22	Jun-22	Sep-22	Dec-22	Mar-23	Jun-23	Sep-23	Dec-23
	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1E	Q2E	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Book & Cash Value (per share)																
Book Value per Share (diluted)	-\$0.01	\$0.03	\$0.35	\$0.29	\$0.26	\$0.26	\$0.21	\$0.22	\$0.07	\$0.04	\$0.03	\$0.03	\$0.02	\$0.00	\$0.00	\$0.01
Cash per Share (diluted)	\$0.20	\$0.29	\$0.34	\$0.29	\$0.25	\$0.24	\$0.20	\$0.17	\$0.04	\$0.02	\$0.01	\$0.01	-\$0.01	-\$0.02	-\$0.02	-\$0.02
Net cash per Share (diluted)	\$0.13	\$0.27	\$0.33	\$0.29	\$0.25	\$0.24	\$0.20	\$0.16	\$0.04	\$0.01	\$0.00	\$0.00	-\$0.01	-\$0.03	-\$0.02	-\$0.02
Source: Company reports and Ascend	liant Capita	l Market	s estima	ites												

Source: Company reports and Ascendiant Capital Markets estimates



NovaBay Pharmaceuticals, Inc.


Cash Flow Statement (\$ mils)	·	Jun-20	Sep-20	Dec-20	2020	Mar-21	Jun-21	Sep-21	Dec-21	2021	Mar-22	Jun-22	Sep-22	Dec-22	2022	Mar-23	Jun-23	Sep-23	Dec-23	2023
Fiscal Year End: December 31	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1E	Q2E	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
														-						
Cash flow from operating activities																				
Net income	(1.6)	(4.5)	(3.2)	(1.8)	(11.0)	(1.5)	(1.9)	(2.3)	(0.2)	(5.8)	(3.4)	(2.6)	(1.0)	0.0	(7.0)	(1.5)	(1.5)	0.0	0.8	(2.1
Depreciation and amortization	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.4	0.1	0.1	0.1	0.1	0.4
Stock comp	0.1	0.1	0.4	0.2	0.8	0.2	0.3	0.2	0.4	1.2	0.3	0.3	0.3	0.3	1.0	0.3	0.3	0.3	0.3	1.0
Other gains/losses				(0.1)	(0.1)					0.0					0.0					0.0
Reserve					0.0					0.0					0.0					0.0
Warrant revaluation	(0.1)	3.8	1.6	(0.0)	5.2				(4.6)	(4.6)					0.0					0.0
Amortization of debt	0.1	0.0	(0.0)	0.0	0.1					0.0					0.0					0.0
Other			(0.1)	0.1	0.0					0.0	(0.3)	(0.3)	(0.3)	(0.3)	(1.0)	(0.3)	(0.3)	(0.3)	(0.3)	(1.0
Changes in operating assets and liabilit	ies:																			
Accounts receivable	0.1	(0.6)	0.3	(0.1)	(0.3)	0.1	(0.2)	0.4	0.2	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	(0.1)	(0.1)	(0.2)	0.2	(0.1)	(0.2)	0.2	(0.3)	0.1	(0.2)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaid expenses & other current as	0.2	(0.5)	0.4	0.1	0.3		0.0	(0.1)	0.0	(0.1)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other assets	0.2	0.2	0.3	0.1	0.8	(0.1)	0.3	0.1	(0.2)	0.0					0.0					0.0
Accounts payable	(0.2)	0.6	(0.1)	(0.0)	0.3	0.3	(0.6)	0.6	(0.4)	(0.2)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued expenses		(0.5)	0.5		0.0					0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred revenue	0.6	(0.4)	(0.1)		0.0		0.0	(0.0)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other liabilities	<u>(0.2)</u>	0.7	<u>(1.2)</u>	<u>(0.1)</u>	<u>(0.8)</u>	<u>(0.1)</u>	<u>(0.1)</u>	<u>(0.1)</u>	0.3	<u>(0.1)</u>					0.0					0.0
Net cash (used in) provided by oper	(0.9)	(1.0)	(1.4)	(1.4)	(4.721)	(1.4)	(2.0)	(1.5)	(4.3)	(9.2)	(3.3)	(2.5)	(0.9)	0.2	(6.6)	(1.4)	(1.4)	0.2	0.9	(1.7
Cash flow from investing activities																				
Purchases of property and equipmer	nt		(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.1)	(0.1)	(0.1)	(0.1)	(0.1)	(0.4)	(0.1)	(0.1)	(0.1)	(0.1)	(0.4
Purchases of short-term investments					0.0					0.0					0.0					0.0
Acquisitions					0.0				(12.0)	(12.0)					0.0					0.0
Other					0.0					0.0					0.0					0.0
Net cash used in investing activities	0.0	0.0	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(12.0)	(12.0)	(0.1)	(0.1)	(0.1)	(0.1)	(0.4)	(0.1)	(0.1)	(0.1)	(0.1)	(0.4
Cash flow from financing activities																				
Issuance of debt	(0.6)	(1.6)	(0.4)	0.0	(2.6)				0.1	0.1					0.0					0.0
Issuance of stock		5.2			5.2		1.8	0.2	14.7	16.7					0.0					0.0
Proceeds from stock option exercise	0.2	0.5	6.4	0.0	7.1					0.0					0.0					0.0
<u>Other</u>					0.0					0.0					0.0					0.0
Cash provided by (used in) financing	(0.4)	4.1	6.0	0.0	9.8	0.0	1.8	0.2	14.8	16.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Effect of exchange rate on cash																				
Net increase (decrease) in cash and	(1.2)	3.1	4.6	(1.5)	5.0	(1.4)	(0.2)	(1.3)	(1.5)	(4.4)	(3.4)	(2.6)	(1.0)	0.0	(7.0)	(1.5)	(1.5)	0.0	0.8	(2.1
Beginning cash and equivalents	6.9	5.7	4.0	13.4	6.9	12.0	10.5	10.3	9.0	12.0	7.5	4.1	1.5	0.0	7.5	0.6	(0.9)	(2.3)	(2.3)	0.6
Ending cash and equivalents	6.9 5.7	5.7 8.8	o.o 13.4	13.4	12.0	12.0	10.5	9.0	9.0 7.5	7.5	4.1	4.1	0.5	0.5	0.6	(0.9)	(0.9)	(2.3)	(2.3)	(1.5
Source: Company reports and Ascendia	-				12.0	10.5	10.3	9.0	1.5	1.5	4.1	1.0	0.0	0.0	0.0	(0.9)	(2.3)	(2.3)	(1.3)	(1.5

rce: Company reports and Ascendiant Capital Markets estimates



ANALYST CERTIFICATION

Each analyst hereby certifies that the views expressed in this report reflect the analyst's personal views about the subject securities or issuers. Each analyst also certifies that no part of the analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The analyst who prepared this report is compensated based upon the overall profitability of Ascendiant Capital Markets, LLC, which may, from time to time, include the provision of investment banking, financial advisory and consulting services. Compensation for research is based on effectiveness in generating new ideas for clients, performance of recommendations, accuracy of earnings estimates, and service to clients.



Report Date Price Report Date Rating Target 25 3/21/2018 B 6.00 5/11/2018 B 26 5.00 27 8/8/2018 B 4.50 28 11/16/2018 B 2.50 29 1/19/2019 B 2.50 30 3/31/2019 B 2.25 31 5/10/2019 B 1.75 32 8/9/2019 B 2.00 33 11/8/2019 B 1.50 34 1/29/2020 B 1.75 35 3/29/2020 B 1.50 36 5/12/2020 B 3.00 37 8/7/2020 B 3.25 38 11/14/2020 B 3.50 39 4/4/2021 B 3.75 40 5/11/2021 B 3.25 41 8/18/2021 B 3.50 42 11/30/2021 B 4.00

• Ascendiant Capital Markets, LLC has not received compensation for advisory or investment banking services from the company in the past 12 months.

IMPORTANT DISCLOSURES

This report has been distributed by Ascendiant Capital Markets, LLC and is for the sole use of our clients. This report is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. This report contains information from various sources, including United States government publications, The Wall Street Journal and other periodicals, Yahoo! Finance and other sources, and is for informational purposes only and is not a recommendation to trade in the securities of the companies mentioned within the report. We seek to update our research and recommendations as appropriate, but the large majority of reports are published at irregular intervals as we consider appropriate and, in some cases, as constrained by industry regulations.



We may have a business relationship with companies covered in this report. Ascendiant Capital Markets, LLC may make a market in the securities of the subject company. We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this report. This report is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any information in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of the investments referred to in this report may fluctuate.

Following are some general risks that can adversely impact future operational and financial performance and share price valuation: (1) industry fundamentals with respect to legislation, mandates, incentives, customer demand, or product pricing; (2) issues relating to competing companies or products; (3) unforeseen developments with respect to management, financial condition or accounting policies or practices; or (4) external factors that affect the interest rates, currency, the economy or major segments of the economy. Past performance is not a guide to future performance, future returns are not guaranteed, and loss of original capital may occur. Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Our report is disseminated primarily electronically, and, in some cases, in printed form. The information contained in this report is not incorporated into the contents of our website and should be read independently thereof. Copyright Ascendiant Capital Markets, LLC. No part of this material may be copied, photocopied or duplicated by any means or redistributed without the prior written consent of Ascendiant Capital Markets, LLC.

Risks & Considerations

Risks to attainment of our share price target include failure of product candidates to demonstrate safety and efficacy in clinical trials, failure to gain regulatory approval for commercial sale, failure to obtain suitable reimbursement, consumer acceptance of products, competition, and changing macroeconomic factors.

Ascendiant Capital Markets, LLC Rating System

BUY: We expect the stock to provide a total return of 15% or more within a 12-month period.

- HOLD: We expect the stock to provide a total return of negative 15% to positive 15% within a 12-month period.
- SELL: We expect the stock to have a negative total return of more than 15% within a 12-month period.

Total return is defined as price appreciation plus dividend yield.

Ascendiant Capital Markets, LLC Rating System

Prior to January 31, 2014, ASCM used the following rating system:

- **Strong Buy:** We expect the stock to provide a total return of 30% or more within a 12-month period.
- **Buy:** We expect the stock to provide a total return of between 10% and 30% within a 12-month period.
- Neutral: We expect the stock to provide a total return of between minus 10% and plus 10% within a 12-month period.
- Sell: We expect the stock to provide a total return of minus 10% or worse within a 12-month period.
- **Speculative Buy:** This rating is reserved for companies we believe have tremendous potential, but whose stocks are illiquid or whose equity market capitalizations are very small, often in the definition of a nano cap (below \$50 million in market cap). In general, for stocks ranked in this category, we expect the stock to provide a total return of 50% or more within a 12-month period. However, because of the illiquid nature of the stock's trading and/or the nano cap nature of the investment, we caution that these investments may not be suitable for all parties.

Total return is defined as price appreciation plus dividend yield.

				Banking Services 2 months
Rating	Count	Percent	Count	Percent
Buy	40	98%	16	40%
Hold	0	0%	0	0%
Sell	1	2%	0	0%
Total	41	100%	16	39%

Ascendiant Capital Markets, LLC Distribution of Investment Ratings (as of January 15, 2022)

Other Important Disclosures

Our analysts use various valuation methodologies including discounted cash flow, price/earnings (P/E), enterprise value/EBITDAS, and P/E to growth rate, among others. Risks to our price targets include failure to achieve financial results, product risk, regulatory risk, general market conditions, and the risk of a change in economic conditions.

Dissemination of Research

Ascendiant Capital Markets, LLC research is distributed electronically via the Thomson Reuters platforms, Bloomberg, Capital IQ and FactSet. Please contact your investment advisor or institutional salesperson for more information.

General Disclaimer

The information and opinions in this report were prepared by Ascendiant Capital Markets, LLC. This information is not intended to be used as the primary basis of investment decisions and because of individual client objectives it should not be construed as advice designed to meet the particular investment needs of any investor. This material is for information purposes only and is not an offer or solicitation with respect to the purchase or sale of any security. The reader should assume that Ascendiant Capital Markets, LLC may have a conflict of interest and should not rely solely on this report in evaluating whether or not to buy or sell securities of issuers discussed herein. The opinions, estimates, and projections contained in this report are those of Ascendiant Capital Markets, LLC as of the date of this report and are subject to change without notice. Ascendiant Capital Markets, LLC endeavors to ensure that the contents have been compiled or derived from sources that we believe are reliable and contain information and opinions that are accurate and complete. However, Ascendiant Capital Markets, LLC makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions contained herein, and accepts no liability whatsoever for any loss arising from any use of, or reliance on, this report or its contents. Information may be available to Ascendiant Capital Markets, LLC, or its affiliates that is not reflected in this report. This report is not to be construed as an offer or solicitation to buy or sell any security.

Additional Disclosures

Ascendiant Capital Markets, LLC is a broker-dealer registered with the United States Securities and Exchange Commission (SEC) and a member of the FINRA and SIPC. Ascendiant Capital Markets, LLC is not a Registered Investment Advisor nor is it an investment advisor registered with the Securities and Exchange Commission or with the securities regulators of any state, and at the present time is not eligible to file for federal registration.